This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clarus Therapeutics Holdings 관리

관리 기준 확인 0/4

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Aug 18

Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies

Dec 01

CEO

Clarus Therapeutics Holdings 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Dudley	Founder & Director	19yrs	US$2.48m	0.0088% $ 5.0
Steve Stark	Vice President of Commercial Analytics & Operations	no data	데이터 없음	데이터 없음
Rozita Passarella	Vice President of Marketing	no data	데이터 없음	데이터 없음
Mike Cleveland	Vice President of Sales	1.1yrs	데이터 없음	데이터 없음
Jay Newmark	Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음
James Holloway	Senior Vice President of Manufacturing & Supply	1.4yrs	데이터 없음	데이터 없음
Lawrence Perkins	Chief Restructuring Officer	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

경험이 풍부한 관리: CRXT.Q's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

This company is no longer active

Clarus Therapeutics Holdings 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022

Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022

Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees

No independent directors

Recent updates

First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022

Nasdaq to Delist Common Stock of Clarus Therapeutics Holdings

Motion for Asset Sale Filed by Clarus Therapeutics Holdings, Inc.

Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from S&P TMI Index

Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from NASDAQ Composite Index

Clarus Therapeutics Holdings Receives a Staff Determination Letter from Nasdaq

Clarus Therapeutics Holdings Inc Contemplates Bankruptcy

Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Clarus Therapeutics Holdings, Inc. announced delayed 10-Q filing

Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees

Clarus Therapeutics Receives Written Notice from the Staff, or the Staff, of the Listing Qualifications Department of the Nasdaq Stock Market

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clarus Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$7.20

No longer forecast to breakeven

Clarus Therapeutics Holdings, Inc. has completed a Composite Units Offering in the amount of $34.497461 million.

Clarus Therapeutics Holdings, Inc. has completed a Composite Units Offering in the amount of $34.497461 million.

Consensus forecasts updated

No longer forecast to breakeven

Clarus Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 30, 2022

Clarus Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 30, 2022

Forecast to breakeven in 2024

Clarus Therapeutics Holdings, Inc. announced that it expects to receive $15.000002 million in funding

Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies

Third quarter 2021 earnings released: US$0.26 loss per share

No independent directors

CEO

리더십 팀

평균 재임 기간